Ned Sonntag
Outermost Hoodoo Doctor
Sanofi-Aventis, Pfizer end studies on 2 diet drugs
By LINDA A. JOHNSON Associated Press Writer
"Nov 5th, 2008 | TRENTON, N.J. -- French drugmaker Sanofi-Aventis said Wednesday it is halting all research on a diet drug sold in Europe, Acomplia, and rival Pfizer Inc. hours later said it is ending research on an experimental weight-loss drug in the same class.
Both drugs work by blocking the pleasure centers that give marijuana smokers the "munchies" -- the cannabinoid type 1, or CB1, receptors..."
Remember the horror a couple of years back with the reverse-engineered 'anti-pleasure' drugs... ? I announce this development, or halting of same, with pleasure.
By LINDA A. JOHNSON Associated Press Writer
"Nov 5th, 2008 | TRENTON, N.J. -- French drugmaker Sanofi-Aventis said Wednesday it is halting all research on a diet drug sold in Europe, Acomplia, and rival Pfizer Inc. hours later said it is ending research on an experimental weight-loss drug in the same class.
Both drugs work by blocking the pleasure centers that give marijuana smokers the "munchies" -- the cannabinoid type 1, or CB1, receptors..."
Remember the horror a couple of years back with the reverse-engineered 'anti-pleasure' drugs... ? I announce this development, or halting of same, with pleasure.
